Want to see IN:NATCAPSUQ full AI Analyst Report?
NATCAPSUQ Stock Chart & Stats
₹145.15
-₹1.02(-0.69%)
At close: 4:00 PM EDT
₹145.15
-₹1.02(-0.69%)
Day’s Range― - ―
52-Week Range₹135.60 - ₹256.70
Previous CloseN/A
Volume10.41K
Average Volume (3M)3.11K
Market Cap
₹1.66B
Enterprise Value₹2.74B
Total Cash (Recent Filing)₹53.75M
Total Debt (Recent Filing)₹1.12B
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Oct 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.4%
Share Statistics
EPS (TTM)-6.25
Shares Outstanding10,411,154
10 Day Avg. Volume1,125
30 Day Avg. Volume3,112
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.47
Price to Sales (P/S)0.55
P/FCF Ratio-9.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong FY2026 Revenue GrowthThe sharp FY2026 revenue increase indicates that customer demand and sales activity expanded despite the company’s profitability challenges. Sustained top-line growth could support operating leverage and broader scale if management can control costs and protect pricing over the next several quarters.
Focused Capsule-Shell BusinessA focused role in the pharmaceutical and nutraceutical supply chain gives Natural Capsules a clearly defined product and customer base. Capsule shells are an established input for dosage products, providing a durable business focus while customers continue producing capsule-based medicines and supplements.
Moderate LeverageDebt at approximately half of equity suggests leverage is not yet excessive and leaves some capacity to manage operations or investments. This relative balance-sheet flexibility may help the company withstand volatility, although its usefulness depends on restoring earnings and cash generation.
Bears Say
Sharp Profitability DeteriorationThe shift to a sizable net loss, alongside negative operating and EBITDA margins, shows that recent revenue growth has not translated into profitable expansion. Persistent margin pressure could weaken reinvestment capacity and make future growth less valuable unless costs or pricing mix improve.
Negative Free Cash FlowNegative free cash flow across both reported years means the business has not internally funded its operating and investment needs. If weak cash conversion persists, Natural Capsules may need external capital, reducing financial flexibility and increasing the risk that growth requires additional funding.
Weaker Equity ReturnsDeclining equity combined with negative return on equity reflects a deterioration in the quality of capital employed. If losses continue, retained capital could erode further, limiting resilience and reducing the company’s ability to fund expansion without relying more heavily on debt or new equity.
Natural Capsules Limited News
NATCAPSUQ FAQ
What was Natural Capsules Limited’s price range in the past 12 months?
Natural Capsules Limited lowest stock price was ₹135.60 and its highest was ₹256.70 in the past 12 months.
What is Natural Capsules Limited’s market cap?
Natural Capsules Limited’s market cap is ₹1.66B.
When is Natural Capsules Limited’s upcoming earnings report date?
Natural Capsules Limited’s upcoming earnings report date is Oct 26, 2026 which is in 14 days.
How were Natural Capsules Limited’s earnings last quarter?
Natural Capsules Limited released its earnings results on Aug 12, 2026. The company reported -₹3.819 earnings per share for the quarter.
Is Natural Capsules Limited overvalued?
According to Wall Street analysts Natural Capsules Limited’s price is currently Overvalued.
Does Natural Capsules Limited pay dividends?
Natural Capsules Limited pays a Annually dividend of ₹1 which represents an annual dividend yield of 0.4%. See more information on Natural Capsules Limited dividends here
What is Natural Capsules Limited’s EPS estimate?
Natural Capsules Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Natural Capsules Limited have?
Natural Capsules Limited has 10,411,154 shares outstanding.
What happened to Natural Capsules Limited’s price movement after its last earnings report?
Natural Capsules Limited reported an EPS of -₹3.819 in its last earnings report. Following the earnings report the stock price went down -3.671%.
Which hedge fund is a major shareholder of Natural Capsules Limited?
Currently, no hedge funds are holding shares in IN:NATCAPSUQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Natural Capsules Limited
Natural Capsules Ltd. specializes in the production and global distribution of hard gelatin and cellulose capsule shells, catering to markets in India and abroad. The company offers a comprehensive array of capsule types, including those guaranteed free from bovine spongiform encephalopathy (BSE) and transmissible spongiform encephalopathy (TSE), shiny, sodium lauryl sulfate (SLS)-free, and halal-certified gelatin variants. Their product line further extends to fast-release, printed gelatin/cellulose, vegetarian, and enteric capsule shells. Beyond manufacturing shells, Natural Capsules Ltd. is also involved in formulating various pharmaceutical products in capsule dosage forms. Established in 1993, the company is headquartered in Bengaluru, India.
Technical Analysis
Alpa Laboratories Limited
―
Bal Pharma Limited
―
Brooks Laboratories Limited
―
Nectar Lifesciences Ltd.
―
Par Drugs and Chemicals Limited
―